[{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TRC253","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Private Placement","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methoxyamine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ National Cancer Institute"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methoxyamine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Alphamab Oncology"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Biocytogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Runway Growth Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Runway Growth Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Runway Growth Capital LLC"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Alphamab Oncology"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by TRACON Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN035 (Envafolimab), a PD-L1 inhibitor with Yervoy was intended for undifferentiated pleomorphic sarcoma & myxofibrosarcoma. However, the company has discontinued its ENVASARC trial.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 01, 2024

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN035 is an investigational PD-L1 antibody, which is currently being evaluated for the treatment of undifferentiated pleomorphic sarcoma & myxofibrosarcoma.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 03, 2024

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN035 (envafolimab) is a single-domain antibody against PD-L1. It isbeing evaluated in phase 2 clinical trials for the treatment of undifferentiated pleomorphic sarcoma & myxofibrosarcoma.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 20, 2023

                          Lead Product(s) : Envafolimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN035 (envafolimab) is a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor, which is investigated for MSI-H/dMMR advanced solid tumors.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 18, 2023

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : KN035 (envafolimab) is a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor, which is investigated for MSI-H/dMMR advanced solid tumors.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 20, 2023

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Alphamab Oncology

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 14, 2022

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : YH001 is an IgG1 antibody against CTLA-4 that has shown enhanced antibody dependent cellular cytotoxicity and complement dependent cytotoxicity in vitro. YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared...

                          Brand Name : YH001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 21, 2022

                          Lead Product(s) : YH001,Envafolimab,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Envafolimab (KN035), a single-domain antibody against PD-L1 is the first approved subcutaneously injected PD-(L)1 inhibitor. Envafolimab is currently being studied in the ENVASARC Phase 2 and a Phase 3 pivotal trial in advanced biliary tract cancer patie...

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 06, 2022

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Envafolimab (KN035), a single-domain antibody against PD-L1 invented by Alphamab Oncology, is the first approved subcutaneously injected PD-(L)1 inhibitor.

                          Brand Name : KN035

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 06, 2022

                          Lead Product(s) : Envafolimab,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Runway Growth Capital LLC

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          10

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : YH001 is an IgG1 antibody targeting CTLA-4,has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab.

                          Brand Name : YH001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 29, 2022

                          Lead Product(s) : YH001,Envafolimab,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Biocytogen

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank